Clinical trials: Advanced Rectal Cancers
Colon Cancer, Rectal Cancer
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.
- Trial name
- NCT01347645
- Testing
- FOLFIRI, E7820
- Where
- 38 sites in United States, Argentina and 4 more
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Advanced Solid Tumor, Gynecologic Cancer
A Study of PY314 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including…
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer
- Trial name
- NCT04691375
- Testing
- PY314, Combination Therapy: PY314 + Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 86 people
- Sponsor
- Ikena Oncology
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Solid Tumor Malignancies, Colorectal Carcinoma
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383.
- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
- Trial name
- NCT07030257
- Testing
- CP-383
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Tasca Therapeutics
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT07066657
- Testing
- MRG007, MRG007 and Bevacizumab
- Where
- 21 sites in United States, China
- Volunteers
- 572 people
- Sponsor
- ArriVent BioPharma, Inc.
Rectal Cancer
A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer
This phase Ib/II study is a prospective, open-label, single arm, nonrandomized study of PEP503(radio-enhancer). There are 2 portions in this study.
- Trial name
- NCT02465593
- Testing
- PEP503, 5-fluorouracil, capecitabine
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- PharmaEngine
Colorectal Cancer, Colorectal Neoplasms
Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for Colorectal Cancer and Advanced Adenoma
This study is to determine how the Mainz Biomed Colorectal Cancer Screening Test works when used in people aged ≥45 years of age and at an average risk of developing colorectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenoma
- Trial name
- reconAAsense (NCT05636085)
- Testing
- Mainz Biomed Colorectal Cancer Screening Test
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Mainz Biomed
Advanced Solid Tumor
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to…
- Trial name
- NCT06307925
- Testing
- HC010
- Where
- China
- Volunteers
- 122 people
- Sponsor
- HC Biopharma Inc.
Gastric Cancer (GC), Colorectal Cancer
Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer and colorectal cancer.NK510 will be administered by intravenous infusion for systemic therapy and…
- Trial name
- NCT07166263
- Testing
- NK510
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors
The primary objective is to determine the safety and tolerability of SH3809 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3809 in solid tumors.
- Trial name
- NCT04843033
- Testing
- SH3809 tablet
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT06549816
- Testing
- sigvotatug vedotin
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Advanced Colorectal Cancer, Colorectal Cancer
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with…
- Trial name
- NCT00498407
- Testing
- CP-4055
- Where
- 4 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Clavis Pharma
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
- Trial name
- NCT04956640
- Testing
- LY3537982, Pembrolizumab, Cetuximab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 540 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Rectal Cancer
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
The main purpose of the study was to define maximum tolerated dose (MTD), recommended Phase II dose (RP2D) safety and tolerability of Peposertib in combination with capecitabine and radiotherapy (RT).
- Trial name
- NCT03770689
- Testing
- Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg
- Where
- 14 sites in United States, Spain
- Volunteers
- 19 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Colorectal Neoplasm, Head and Neck Neoplasm
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
This study is proposed to evaluate the efficacy and safety of temozolomide, an oral anti-cancer agent, in a participant population selected for a biomarker.
- Conditions
- Colorectal Neoplasm, Head and Neck Neoplasm, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasm
- Trial name
- NCT00423150
- Testing
- Temozolomide
- Volunteers
- 86 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.